Fate’s Phase I NK Cell Therapy Sparks Optimism, But Longer Follow-Up Needed
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.
You may also be interested in...
Intellia continues to expand across immuno-oncology, adding the promise of natural killer cells to its pipeline.
Novartis hopes a CAR-T with rapid manufacturing will be a winner, while novel bispecific antibodies in lymphoma and myeloma will make appearances, along with next-generation PI3K and BTK inhibitors.
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.